Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Lipid Parameters in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2023, 7 (2), s115. https://doi.org/10.25251/skin.7.supp.115.